Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
400 participants
OBSERVATIONAL
2023-07-20
2026-07-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China
NCT05510219
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
NCT05899621
Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)
NCT06170216
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
NCT03520920
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
NCT05846750
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
the younger cohort (aged ≥ 18 and \< 60 years at the start of treatment)
Obinutuzumab
obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
Cohort 2
the older cohort (aged ≥ 60 years at the start of treatment)
Obinutuzumab
obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Obinutuzumab
obinutuzumab (G)-contained regimens, including GB, G-CHOP, and G-CVP.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be diagnosed with grade 1-3a follicular Lymphoma, Marginal zone lymphoma;
* Previously untreated or relapsed or refractory patients;
* Patients who started treatment with otuzumab between June 2021 and April 2023.
Exclusion Criteria
* Patients who, in the opinion of the investigator, are Discomfort for any other reason to participate in this study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Affiliated Hospital of Nantong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wenyu Shi
Director, Department of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changzhou No.2 People's Hospital
Changzhou, Jiangsu, China
The First People's hospital of Changzhou
Changzhou, Jiangsu, China
Huai'an First People's hospital
Huai'an, Jiangsu, China
Jiangyin People's Hospital
Jiangyin, Jiangsu, China
Jingjiang People's Hospital
Jingjiang, Jiangsu, China
The first people's hospital of Lianyungang
Lianyungang, Jiangsu, China
The second people's hospital of Lianyungang
Lianyungang, Jiangsu, China
Jiangsu Province Hospital of Chinese Medicine
Nanjing, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Nanjing Jiangning Hospital
Nanjing, Jiangsu, China
Nantong Tumor Hospital
Nantong, Jiangsu, China
Affiliated Hospital of Nantong University
Nanyang, Jiangsu, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Jiangsu Taizhou People's Hospital
Taizhou, Jiangsu, China
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Wuxi People's Hospital
Wuxi, Jiangsu, China
Wuxi Second People's Hospital
Wuxi, Jiangsu, China
Yancheng No.1 People's Hospital
Yancheng, Jiangsu, China
Yancheng Third People's Hospital
Yancheng, Jiangsu, China
Subei People's Hospital
Yangzhou, Jiangsu, China
Yixing People's Hospital
Yixing, Jiangsu, China
Zhangjiagang First People's Hospital
Zhangjiagang, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Zhenjiang First People's Hospital
Zhenjiang, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Xuzhang Lu, PhD
Role: primary
Weiying Gu, PhD
Role: primary
Liang Yu, PhD
Role: primary
Maozhong Xu, PhD
Role: primary
Miao Sun, PhD
Role: primary
Tao Jia, PhD
Role: primary
Wanchuan Zhuang, PhD
Role: primary
Haiwen Ni, PhD
Role: primary
Jianyong Li, PhD
Role: primary
Jinning Shi, PhD
Role: primary
Xiaohong Xu, PhD
Role: primary
Bingzong Li, PhD
Role: primary
Jianfeng Zhu, PhD
Role: primary
Haiying Hua, PhD
Role: primary
Yun Zhuang, PhD
Role: primary
Zhi Wang, PhD
Role: primary
Yuexin Cheng, PhD
Role: primary
Naitong Sun, PhD
Role: primary
Xiaoyan Xie, PhD
Role: primary
Yunping Zhang, PhD
Role: primary
Min Xu, PhD
Role: primary
Xiaoming Fei, PhD
Role: primary
Jun Qian, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JCLG-23-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.